Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Capital Leases (2020 - 2025)

Historic Capital Leases for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $3.2 million.

  • SAB Biotherapeutics' Capital Leases fell 455.94% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 455.94%. This contributed to the annual value of $3.3 million for FY2024, which is 417.04% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Capital Leases of $3.2 million as of Q3 2025, which was down 455.94% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Capital Leases ranged from a high of $3.8 million in Q4 2021 and a low of $3.2 million during Q3 2025
  • In the last 5 years, SAB Biotherapeutics' Capital Leases had a median value of $3.4 million in 2023 and averaged $3.5 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Capital Leases plummeted by 352.93% in 2022, and later crashed by 590.25% in 2024.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Capital Leases stood at $3.8 million in 2021, then fell by 3.53% to $3.6 million in 2022, then fell by 5.82% to $3.4 million in 2023, then decreased by 4.17% to $3.3 million in 2024, then decreased by 3.49% to $3.2 million in 2025.
  • Its Capital Leases stands at $3.2 million for Q3 2025, versus $3.2 million for Q2 2025 and $3.2 million for Q1 2025.